Blue Owl Capital Holdings’s Janux Therapeutics JANX Stock Holding History

Blue Owl Capital Holdings’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$1.38M	–	81
2025 Q4	$1.38M	Buy	+100,000	New	+$2.35M	0.43%	36
2024 Q4	–	Sell	-80,000	Closed	-$3.63M	–	97
2024 Q3	$3.63M	Buy	80,000 +40,000	+100%	+$1.74M	0.7%	30
2024 Q2	$1.68M	Buy	+40,000	New	+$1.88M	0.47%	32

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Blue Owl Capital Holdings's JANX Position: Q1 2026 in Review

Blue Owl Capital Holdings sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 100,000 shares — an estimated $1.38M sold.

Blue Owl Capital Holdings first reported a position in JANX in Q2 2024 and held it in 3 quarters. The position peaked at $3.63M in Q3 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Blue Owl Capital Holdings reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
Blue Owl Capital Holdings sold 100,000 Janux Therapeutics shares in Q1 2026, an estimated $1.38M.
Blue Owl Capital Holdings first reported a position in Janux Therapeutics in Q2 2024 and held it in 3 quarters.
Blue Owl Capital Holdings's Janux Therapeutics position peaked at $3.63M in Q3 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.